Gsk (GSK) Other Operating Expenses (2009 - 2026)

Over the trailing twelve months to Sep 30, 2026, Gsk reported Other Operating Expenses of $21.3 billion, up 35.6% year-over-year; for the year ended Dec 31, 2025, it came in at $9.92 billion, up 21.3% from the prior year.

• Other Operating Expenses has increased in each of the last three years, with a five-year compound annual growth rate of 10.0% (years ended Dec 2020 to Dec 2025).
• Going back by year, Other Operating Expenses was $8.18 billion in the year ended Dec 31, 2024 (+5.7%), $7.74 billion in the year ended Dec 31, 2023 (+14.0%), $6.79 billion in the year ended Dec 31, 2022 (-1.6%) and $6.91 billion in the year ended Dec 31, 2021 (+12.2%).
• The five-year range for quarterly Other Operating Expenses is $1.76 billion (the quarter ended Mar 31, 2022) to $10.94 billion (the quarter ended Dec 31, 2025).
• Year-over-year, Other Operating Expenses has increased for eight consecutive quarters, with growth averaging 26.0% over the last eight quarters.
• The fastest year-over-year change in Other Operating Expenses over five years came in the quarter ended Dec 31, 2022 (growth of 254.2%), and the weakest in the quarter ended Sep 30, 2022 (a decline of 18.0%).
• Business Quant data shows GSK's Other Operating Expenses at $4.89 billion (quarter ended Jun 30, 2026), $2.51 billion (quarter ended Mar 31, 2026) and $10.94 billion (quarter ended Dec 31, 2025) in the three quarters before the quarter ended Sep 30, 2026.